MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care (NCT05287191) | Clinical Trial Compass
UnknownPhase 3
MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care
Canada200 participantsStarted 2022-01-05
Plain-language summary
A multi-centre, non-blinded, comparative effectiveness, randomised controlled trial. Patients will be prospectively enrolled from Critical Care Units and will be assessed for study enrollment based on inclusion/exclusion criteria at the time of the onset of fast atrial fibrillation (AF)(irregular and often rapid heart rate). The authors hypothesize that high dose Magnesium Sulphate with the addition of Digoxin as a second line treatment will improve the success rate in returning the heart to normal rhythm as well as speed of resolution of critical illness in new onset rapid atrial fibrillation in the critically ill cared for in general ICUs.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Admitted to a participating hospital ICU
✓. A newly documented episode of fast Atrial Fibrillation with heart rate \>120/min confirmed by a 12-lead ECG assessment regardless of baseline rhythm (note- The AF can be acute or chronic diagnosis)
✓. Undergoing, or able to commence continuous electrocardiographic monitoring ("telemetry") as part of their routine clinical care
✓. Treating physician determines the patient has clinically significant AF that requires medical treatment
Exclusion criteria
✕. Age \<18 years
✕. Palliative goals of care or expected to die in the next 12 hours
✕. Fast Atrial Fibrillation (\>120/min) present for \> 48 hours
✕. Treatment with digoxin or a class I or III anti-arrhythmic medication within the preceding 24 hours
✕. MgSO4 dose of \> 3g IV in the last 2 hours.
What they're measuring
1
Heart rate control (<110 beats per minute) and/or restoration of normal sinus
. History of high grade Atrio-Ventricular conduction block or bradyarrhythmia without pacemaker
✕. Non-cardiac indication or contraindication to one of the study treatments (hypertensive disorders of pregnancy, pre-term labour, neuromuscular junction disorders i.e. known Myasthenia gravis; documented prior history of amiodarone toxicity or relative contraindication such as thyroid disease, cirrhosis, pulmonary fibrosis, etc.)
✕. Recent cardiac surgery during index hospital admission